Butterfly Network, Inc. (BFLY) Stock Analysis and Metrics

Sector: Healthcare Industry: Medical Devices CIK: 0001804176

Market Cap 947.72 Mn

P/E -12.37

P/S 9.71

Div. Yield 0.00

ROIC (Qtr) -0.43

Revenue Growth (1y) (Qtr) 41.00

Add ratio to table...

About

Butterfly Network, Inc., a digital health company, is revolutionizing the healthcare industry with its innovative combination of portable ultrasound technology, intuitive software, and educational solutions. The company's main business activities involve the development and marketing of handheld, portable ultrasound devices that can be used by healthcare practitioners to perform ultrasound imaging. Butterfly Network operates in the digital health sector, specifically focusing on ultrasound technology. The company's operations span across various...

Butterfly Network, Inc., a digital health company, is revolutionizing the healthcare industry with its innovative combination of portable ultrasound technology, intuitive software, and educational solutions. The company's main business activities involve the development and marketing of handheld, portable ultrasound devices that can be used by healthcare practitioners to perform ultrasound imaging. Butterfly Network operates in the digital health sector, specifically focusing on ultrasound technology. The company's operations span across various countries, including the United States, Europe, and Asia.

The company's primary products are the Butterfly iQ+ and iQ3, which are handheld, portable ultrasound devices that utilize semiconductor technology to provide high-quality images. The Butterfly iQ+ is priced at approximately $2,700 per device, making it an affordable and high-quality alternative to traditional cart-based equipment. The Butterfly iQ3 is priced at $3,899 per device and offers advanced features such as iQ Slice and iQ Fan, which provide automated image capture modes and real-time guidance. These products are designed to be easy to use, providing high-quality images, and thus, making them accessible to a wider range of healthcare professionals beyond traditional ultrasound users.

Butterfly Network's competitive advantage lies in its innovative technology, ease of use, and affordability. The company's Ultrasound-on-Chip technology is a game-changer, enabling whole-body imaging on a single probe using digital semiconductor technology. This technology makes it more affordable and accessible than traditional piezoelectric crystal-based ultrasound devices, providing a significant edge over competitors. Moreover, the company's business strategy is focused on staying at the leading edge of technical innovation, nurturing and growing its core capabilities and clinical pathways, capturing new and adjacent markets, leveraging its Ultrasound-on-Chip technology into non-competitive markets through partnerships, and optimizing its resources.

The global ultrasound market is over $100 billion, and Butterfly Network is addressing an unmet need across an addressable market of over 40 million healthcare practitioners, including approximately 2 million veterinarians and veterinary technicians, 10 million medical doctors, and 30 million nurses and midwives worldwide. The company sells its products and services through a direct sales force, distributors, and its e-commerce channel, generating revenue of $65.9 million and $73.4 million in the years ended December 31, 2023 and 2022, respectively.

Butterfly Network's current product portfolio includes a combination of hardware and software, including the Butterfly iQ+ and iQ3 probes, software subscriptions, and professional services. The company offers cloud-based software solutions to healthcare systems, tele-guidance, in-app educational tutorials, formal education programs through its Butterfly Academy software and Butterfly Certified courses, as well as professional services for large-scale deployments. Butterfly's enterprise platform is designed to support the scaled integration and deployment of its ultrasound hardware and Compass software across hospitals and health systems to empower image-informed clinical decisions from the bedside and encounter-based workflow.

The company's software subscription options allow users to upload scanned images to its HIPAA-compliant cloud, which has unlimited storage and links to electronic medical records (EMRs), hospital and office systems, allowing for seamless transfer of images that can also be accessed from a desktop computer. Furthermore, Butterfly offers educational tools to enable users to quickly gain proficiency in conducting exams, including hundreds of educational videos taught by experts. The company's platform features education tools to enable users to quickly gain proficiency in conducting exams, including written walkthroughs and reference imagery to guide real-time educational scanning, enhancing the learning process.

Investment thesis

Bull case

Butterfly’s recent quarter demonstrated a clear shift from a “sell‑probes‑only” model to a platform‑centric strategy that positions the company for significant scale. The launch of iQ3 in 2024 and its rapid adoption, now accounting for 85 % of probe volume, underscores the market’s appetite for a semiconductor‑based, cloud‑connected device. Coupled with the announced entry of P5.1 into full‑scale production and the planned Apollo AI chip, the firm is poised to deliver higher‑quality imaging at lower cost, thereby reinforcing its competitive advantage over legacy piezo‑based handhelds. This technological leap, combined with an increasing focus on AI‑enabled clinical workflows, should accelerate enterprise sales and deepen penetration into hospital systems worldwide.
Clinical validation studies have become a powerful catalyst for adoption, yet management has not heavily highlighted them in public messaging. The Rutgers study, which documented a 35 % improvement in clinical management and a 30 % reduction in length of stay, offers hard economic data that can be leveraged to justify the higher cost of enterprise licenses. Similarly, the gestational‑age AI tool deployed in Malawi and Uganda demonstrates the platform’s applicability in low‑resource settings, potentially opening access to emerging markets that large competitors have not yet penetrated. These proof points not only support a higher valuation of the software component but also signal a broader shift toward value‑based reimbursement models that favor point‑of‑care solutions.
Security and regulatory compliance have been a differentiator that has been underemphasized by the market. Butterfly’s recent ISO 27001 certification, along with other international security accreditations, signals a robust cloud posture that is attractive to large health systems wary of data breaches. The company’s early adoption of FedRAMP and other U.S. government standards positions it favorably for federal contracts, which could drive a significant portion of future revenue. The strategic emphasis on secure, cloud‑enabled workflows may also reduce the time to market for future AI applications, creating a virtuous cycle of adoption and revenue growth.
The pipeline, while subject to seasonal timing, shows increasing activity as evidenced by the 30 % increase in U.S. and international revenue in Q3. Management’s assertion that the “cloud is lifting” reflects a broader acceptance of the platform’s enterprise software, which has already generated steady software and services revenue. With Compass AI on the cusp of launch, the company is likely to capture recurring subscription revenue, thereby improving the quality of earnings and providing a more predictable cash flow profile. This shift toward software‑driven margins should translate into higher profitability once the current operating leverage constraints are mitigated.
Butterfly’s balance sheet has improved markedly, with cash and equivalents rising to $148 million from $88 million a year earlier, giving the company a substantial runway to invest in R&D and go‑to‑market initiatives. The company’s non‑cash inventory write‑down, while painful on GAAP earnings, is a one‑off event that has sharpened the cost structure and brought adjusted gross margin to 64 %. This indicates that the firm’s underlying economics are becoming healthier and that the company can sustain its growth trajectory without additional capital injections for the near term. The strong cash position also offers a buffer against potential macroeconomic headwinds that could impact payment timing for large hospital contracts.

Butterfly’s recent quarter demonstrated a clear shift from a “sell‑probes‑only” model to a platform‑centric strategy that positions the company for significant scale. The launch of iQ3 in 2024 and its rapid adoption, now accounting for 85 % of probe volume, underscores the market’s appetite for a semiconductor‑based, cloud‑connected device. Coupled with the announced entry of P5.1 into full‑scale production and the planned Apollo AI chip, the firm is poised to deliver higher‑quality imaging at lower cost, thereby reinforcing its competitive advantage over legacy piezo‑based handhelds. This technological leap, combined with an increasing focus on AI‑enabled clinical workflows, should accelerate enterprise sales and deepen penetration into hospital systems worldwide.
Clinical validation studies have become a powerful catalyst for adoption, yet management has not heavily highlighted them in public messaging. The Rutgers study, which documented a 35 % improvement in clinical management and a 30 % reduction in length of stay, offers hard economic data that can be leveraged to justify the higher cost of enterprise licenses. Similarly, the gestational‑age AI tool deployed in Malawi and Uganda demonstrates the platform’s applicability in low‑resource settings, potentially opening access to emerging markets that large competitors have not yet penetrated. These proof points not only support a higher valuation of the software component but also signal a broader shift toward value‑based reimbursement models that favor point‑of‑care solutions.
Security and regulatory compliance have been a differentiator that has been underemphasized by the market. Butterfly’s recent ISO 27001 certification, along with other international security accreditations, signals a robust cloud posture that is attractive to large health systems wary of data breaches. The company’s early adoption of FedRAMP and other U.S. government standards positions it favorably for federal contracts, which could drive a significant portion of future revenue. The strategic emphasis on secure, cloud‑enabled workflows may also reduce the time to market for future AI applications, creating a virtuous cycle of adoption and revenue growth.
The pipeline, while subject to seasonal timing, shows increasing activity as evidenced by the 30 % increase in U.S. and international revenue in Q3. Management’s assertion that the “cloud is lifting” reflects a broader acceptance of the platform’s enterprise software, which has already generated steady software and services revenue. With Compass AI on the cusp of launch, the company is likely to capture recurring subscription revenue, thereby improving the quality of earnings and providing a more predictable cash flow profile. This shift toward software‑driven margins should translate into higher profitability once the current operating leverage constraints are mitigated.
Butterfly’s balance sheet has improved markedly, with cash and equivalents rising to $148 million from $88 million a year earlier, giving the company a substantial runway to invest in R&D and go‑to‑market initiatives. The company’s non‑cash inventory write‑down, while painful on GAAP earnings, is a one‑off event that has sharpened the cost structure and brought adjusted gross margin to 64 %. This indicates that the firm’s underlying economics are becoming healthier and that the company can sustain its growth trajectory without additional capital injections for the near term. The strong cash position also offers a buffer against potential macroeconomic headwinds that could impact payment timing for large hospital contracts.

Bear case

The GAAP gross margin of negative 17.5 % in Q3 is a stark reminder that the company is still grappling with significant cost distortions. The $17.4 million inventory write‑down, a consequence of an overestimation of iQ+ demand, demonstrates the volatility of the company’s supply chain assumptions. Such material write‑downs can erode investor confidence and may prompt further adjustments if the company misjudges future chip demand or faces similar inventory misalignments. Until the company can reliably forecast demand and optimize its inventory cycles, the GAAP margin risk remains a pressing concern.
Butterfly’s cash burn, though reduced, remains substantial relative to its revenue base. The adjusted EBITDA loss of $8.1 million in Q3, alongside a net loss of $33.0 million, indicates that the firm is not yet generating positive operating cash flow. Even with a strong cash balance, continued cash outflows for R&D, sales, and marketing could deplete reserves if enterprise deals do not materialize as expected. This creates a scenario where the company may need to raise additional capital, potentially diluting shareholders or diverting focus from product development.
Enterprise adoption has been slower than anticipated, as evidenced by the company’s candid admission of purchase delays driven by macro‑economic conditions. The Q&A highlighted that hospitals are postponing capital expenditures due to broader economic pressures, which directly impacts the company’s ability to close large deals. Moreover, the reliance on “enterprise sales” to drive growth exposes the business to cyclical capital budgets that are subject to payer negotiations and reimbursement policy changes. These factors could dampen revenue growth and increase the time horizon to reach breakeven.
Management’s focus on education as a barrier to adoption, while valid, is not a scalable solution for the enterprise market. The company’s current strategy of in‑person training and advanced AI tools may not sufficiently address the skill gaps in large health systems, where standardized protocols and regulatory oversight require more robust validation. Additionally, the churn in individual subscription revenue, driven by lower renewal rates, suggests that the customer lifetime value may be lower than projected, especially if enterprise customers do not adopt the subscription model as aggressively. This risk could undermine the anticipated shift toward recurring revenue streams.
Competitive pressure from larger incumbents cannot be ignored. The market still hosts a number of well‑capitalized companies that have recently invested in semiconductor‑based handhelds and cloud platforms, such as those highlighted in industry awards. These players possess deeper pockets for R&D and marketing, allowing them to potentially out‑compete Butterfly in price, feature set, and distribution channels. If competitors successfully bring their own AI‑enabled, secure cloud solutions to market, Butterfly’s unique value proposition may erode, forcing the company into a price‑war scenario.

The GAAP gross margin of negative 17.5 % in Q3 is a stark reminder that the company is still grappling with significant cost distortions. The $17.4 million inventory write‑down, a consequence of an overestimation of iQ+ demand, demonstrates the volatility of the company’s supply chain assumptions. Such material write‑downs can erode investor confidence and may prompt further adjustments if the company misjudges future chip demand or faces similar inventory misalignments. Until the company can reliably forecast demand and optimize its inventory cycles, the GAAP margin risk remains a pressing concern.
Butterfly’s cash burn, though reduced, remains substantial relative to its revenue base. The adjusted EBITDA loss of $8.1 million in Q3, alongside a net loss of $33.0 million, indicates that the firm is not yet generating positive operating cash flow. Even with a strong cash balance, continued cash outflows for R&D, sales, and marketing could deplete reserves if enterprise deals do not materialize as expected. This creates a scenario where the company may need to raise additional capital, potentially diluting shareholders or diverting focus from product development.
Enterprise adoption has been slower than anticipated, as evidenced by the company’s candid admission of purchase delays driven by macro‑economic conditions. The Q&A highlighted that hospitals are postponing capital expenditures due to broader economic pressures, which directly impacts the company’s ability to close large deals. Moreover, the reliance on “enterprise sales” to drive growth exposes the business to cyclical capital budgets that are subject to payer negotiations and reimbursement policy changes. These factors could dampen revenue growth and increase the time horizon to reach breakeven.
Management’s focus on education as a barrier to adoption, while valid, is not a scalable solution for the enterprise market. The company’s current strategy of in‑person training and advanced AI tools may not sufficiently address the skill gaps in large health systems, where standardized protocols and regulatory oversight require more robust validation. Additionally, the churn in individual subscription revenue, driven by lower renewal rates, suggests that the customer lifetime value may be lower than projected, especially if enterprise customers do not adopt the subscription model as aggressively. This risk could undermine the anticipated shift toward recurring revenue streams.
Competitive pressure from larger incumbents cannot be ignored. The market still hosts a number of well‑capitalized companies that have recently invested in semiconductor‑based handhelds and cloud platforms, such as those highlighted in industry awards. These players possess deeper pockets for R&D and marketing, allowing them to potentially out‑compete Butterfly in price, feature set, and distribution channels. If competitors successfully bring their own AI‑enabled, secure cloud solutions to market, Butterfly’s unique value proposition may erode, forcing the company into a price‑war scenario.

Product and Service Breakdown of Revenue (2025)

Segments Breakdown of Revenue (2025)

Peer comparison

Companies in the Medical Devices

S.No.	Ticker	Company	Market Cap	P/E	P/S	Total Debt (Qtr)
1	ABT	Abbott Laboratories	177.36 Bn	27.31	4.00	12.93 Bn
2	SYK	Stryker Corp	124.60 Bn	38.40	4.96	15.86 Bn
3	MDT	Medtronic plc	109.93 Bn	23.82	3.10	28.07 Bn
4	BSX	Boston Scientific Corp	93.15 Bn	31.94	4.64	11.44 Bn
5	EW	Edwards Lifesciences Corp	46.49 Bn	43.68	7.66	0.60 Bn
6	PHG	Koninklijke Philips Nv	29.40 Bn	25.00	1.46	9.41 Bn
7	DXCM	Dexcom Inc	24.14 Bn	28.78	5.18	-
8	STE	STERIS plc	21.56 Bn	30.26	3.70	1.90 Bn

Research Tools

Butterfly Network, Inc. (NYSE: BFLY)

About

Investment thesis

Bull case

Bear case

Product and Service Breakdown of Revenue (2025)

Segments Breakdown of Revenue (2025)

Peer comparison

Research Tools

Butterfly Network, Inc. (NYSE: BFLY)

About

Investment thesis

Bull case

Bear case

Product and Service Breakdown of Revenue (2025)

Segments Breakdown of Revenue (2025)

Peer comparison

Create an account

Sign In

Reset Password